You just read:

Zavante Therapeutics' ZOLYD™ Met Primary Endpoint In Pivotal ZEUS Study For Treatment Of Complicated Urinary Tract Infections

News provided by

Zavante Therapeutics, Inc.

Apr 06, 2017, 00:01 ET